Acute Blood Flow Restriction Walking on Immune Cell Phenotype and Function
NCT07928531, Not applicable, Recruiting, University of British Columbia
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Acute Blood Flow Restriction Walking on Immune Cell Phenotype and Function | ClinicalTrials.gov |
| NCT number | NCT07928531 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 20 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University of British Columbia | ClinicalTrials.gov |
| Conditions | Type 2 Diabetes | ClinicalTrials.gov |
| Interventions | Exercise with BFR, Exercise | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in white blood cell count before, during, and after exercise. | Pre-exercise, during 32 minute of exercise, immediately post-exercise | The white blood cell count will be measured using a hematology analyzer before, during, and after exercise. | ClinicalTrials.gov |
| Secondary | Change in monocyte count before, during, and after exercise | Pre-exercise, during 32 minute of exercise, immediately post-exercise | The monocyte count will be measured using a hematology analyzer before, during, and after exercise. | ClinicalTrials.gov |
| Secondary | Change in neutrophil count before, during, and after exercise | Pre-exercise, during 32 minute of exercise, immediately post-exercise | The neutrophil count will be measured using a hematology analyzer before, during, and after exercise. | ClinicalTrials.gov |
| Secondary | Change in eosinophil count before, during, and after exercise | Pre-exercise, during 32 minute of exercise, immediately post-exercise | The eosinophil count will be measured using a hematology analyzer before, during, and after exercise. | ClinicalTrials.gov |
| Secondary | Change in CD66b+ expression before, during, and after exercise | Pre-exercise, during 32 minute of exercise, immediately post-exercise | The CD66b+ expression will be measured using flow cytometry before, during, and after exercise. | ClinicalTrials.gov |
| Secondary | Change in CD11b+ expression before, during, and after exercise | Pre-exercise, during 32 minute of exercise, immediately post-exercise | The CD11b+ expression will be measured using flow cytometer before, during, and after exercise | ClinicalTrials.gov |
| Secondary | Change in CD63+ expression before, during, and after exercise | Pre-exercise, during 32 minute of exercise, immediately post-exercise | The CD63+ expression will be measured using flow cytometry before, during, and after exercise. | ClinicalTrials.gov |
| Secondary | Change in % of classical monocytes before, during, and after exercise | Pre-exercise, during 32 minute of exercise, immediately post-exercise | The % of classical monocytes will be measured using flow cytometry before, during, and after exercise. | ClinicalTrials.gov |
| Secondary | Change in % of intermediate monocytes before, during, and after exercise | Pre-exercise, during 32 minute of exercise, immediately post-exercise | The % of intermediate monocytes will be measured using flow cytometry before, during, and after exercise. | ClinicalTrials.gov |
| Secondary | Change in % of non-classical monocytes before, during, and after exercise | Pre-exercise, during 32 minute of exercise, immediately post-exercise | The % of non-classical monocytes will be measured using flow cytometry before, during, and after exercise. | ClinicalTrials.gov |
| Secondary | Change in TLR-4 expression on classical monocytes before, during, and after exercise | Pre-exercise, during 32 minute of exercise, immediately post-exercise | The TLR-4 expression on classical monocytes will be measured using flow cytometry before, during, and after exercise. | ClinicalTrials.gov |
| Secondary | Change in TLR-4 expression on intermediate monocytes before, during, and after exercise | Pre-exercise, during 32 minute of exercise, immediately post-exercise | The TLR-4 expression on intermediate monocytes will be measured using flow cytometry before, during, and after exercise. | ClinicalTrials.gov |
| Secondary | Change in TLR-4 expression on non-classical monocytes before, during, and after exercise | Pre-exercise, during 32 minute of exercise, immediately post-exercise | The TLR-4 expression on non-classical monocytes will be measured using flow cytometry before, during, and after exercise. | ClinicalTrials.gov |
| Secondary | Change in plasma IL-6 before, during, and after exercise | Pre-exercise, during 32 minute of exercise, immediately post-exercise | The plasma IL-6 concentration will be measured using a multiplex assay before, during, and after exercise | ClinicalTrials.gov |
| Secondary | Change in plasma IL-10 before, during, and after exercise | Pre-exercise, during 32 minute of exercise, immediately post-exercise | The plasma IL-10 concentration will be measured using a multiplex assay before, during, and after exercise. | ClinicalTrials.gov |
| Secondary | Change in plasma TNF-α before, during, and after exercise | Pre-exercise, during 32 minute of exercise, immediately post-exercise | The plasma TNF-α concentration will be measured using a multiplex assay before, during, and after exercise | ClinicalTrials.gov |
| Secondary | Change in 4-h LPS-induced TNF-α before and after exercise | Pre-exercise, immediately post-exercise | The LPS-induced TNF-α concentration will be measured from whole-blood culture supernatant using an ELISA before and after exercise. | ClinicalTrials.gov |
| Secondary | Change in 4-h LPS+IL10-induced TNF-α before and after exercise | Pre-exercise, immediately post-exercise | The LPS+IL10-induced TNF-α concentration will be measured from whole-blood culture supernatant using an ELISA before and after exercise. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)